Clinical Trial: Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Changes of Cerebral Glucose Metabolism Associated With the Fear Network Activity Before and After 12 Weeks of Escitalpram Treatment in Panic Disorder
Brief Summary:
Panic disorder is one of the most prevalent psychiatric disorders and recently abnormal fear network is known to be implicated in the pathophysiology of panic disorder. The fear network involves many brain regions such as amygdala, hippocampus, periaqueductal gray (PAG), locus coeruleus, parahippocampal gyrus, frontal cortex, and thalamus. Escitalopram, a highly selective serotonin reuptake inhibitor, is usually effective for panic dis order, but there is little information on how escitalopram affects the fear network.
The specific aim of this study is to test the following hypotheses using 18F-FDG positron emission tomography (PET)
- Patients with panic disorder will show abnormal activity of the fear network compared to healthy comparison subjects.
- Patients with panic disorder will show normalized activity of the fear network after 12-weeks of treatment with escitalopram.
- The changes of fear work after the treatment will be associated with psychological variables and neurohormones.
Detailed Summary:
Sponsor: Samsung Medical Center
Current Primary Outcome: 18FDG-PET, PDSS & HAM-A [ Time Frame: 12 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Samsung Medical Center
Dates:
Date Received: October 6, 2008
Date Started: March 2007
Date Completion:
Last Updated: July 21, 2011
Last Verified: July 2011
